UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): November 1, 2007
Bio-Matrix
Scientific Group, Inc.
(Exact
Name of Company as Specified in Charter)
|
Delaware
|
0-32201
|
33-0824714
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
8885
Rehco Road, San Diego, California 92121
(Address
of Principal Executive Offices, Zip Code)
Company’s
telephone number, including area code: (619) 398-3517 ext. 308
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the Company under any of the Following
provisions:
[
] Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425).
[
] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
[
] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
[
] Pre-commencement communications pursuant to Rule
13e-4(c) under the exchange Act (17 CFR 240.13e-4(c)).
Item
8.01 Other Events
On
November 1, 2007, Bio-Matrix Scientific Group, Inc. was granted a Biologics
license (“License”) from the Department of Health Services of the State of
California. This License permits Bio-Matrix Scientific Group, Inc.’s current
facility to accept and store cord blood (Stem Cells), whole blood, and various
blood related specimens for cryogenic short and long term storage.
Item
9.01 Financial Statements and Exhibits
(d) 99.1
Press Release issued by Bio Matrix Scientific Group, Inc. dated
November 5, 2007
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
BIO-MATRIX
SCIENTIFIC GROUP, INC.
By:
/s/
David Koos
David
Koos
Chief
Executive Officer
Dated:
November 4, 2007